浏览器的缓存机制 - 一只菜鸟攻城狮啊 - 博客园:2021-5-9 · 目的 浏览器缓存（Browser Caching）是为了节约网络的资源加速浏览，浏览器在用户磁盘上对最近请求过的文档进行存储，当访问者再次请求这个页面时，浏览器就可以从本地磁盘显示文档，这样就可以加速

电脑国内google加速软件

Enhanced Formulation1Simplified device2

LEARN MORE

电脑国内google加速软件

The only GLP-1 RA with continuous-release microsphere technology1

LEARN MORE
菜鸟加速器

电脑国内google加速软件

Enhanced formulation1 Simplified device2

LEARN MORE

电脑国内google加速软件

The only GLP-1 RA with
continuous-release microsphere technology1

LEARN MORE

Glucose Fluctuation in

电脑国内google加速软件

LEARN MORE免费科学上外网 app

SAVINGS CARD

电脑国内google加速软件

电脑国内google加速软件

open isi

WARNING: RISK OF THYROID C-CELL TUMORS

  • Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON or BYDUREON BCise cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human relevance of exenatide 菜鸟加速器官方 rodent thyroid C-cell tumors has not been determined

  • BYDUREON and BYDUREON BCise are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with the use of BYDUREON or BYDUREON BCise and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with BYDUREON or BYDUREON BCise

CONTRAINDICATIONS

  • Personal or family history of MTC, patients with免费科学上外网 app

  • 老菜鸟——【加速器×2】『我运气真好』_哔哩哔哩 (゜-゜)つロ ...:2021-1-3 · 我用两个加速器，你网速还不行？我得到我想要的枪了***UP 主 老菜鸟——【加速器×2】『我运气真好』 游戏 网络游戏 2021-01-03 12:06:24--播放 · --弹幕 未经作者授权，禁止转载-- -- -- -- 稿件投诉 ...

  • History of drug-induced, immune-mediated thrombocytopenia from exenatide products

WARNINGS AND PRECAUTIONS

  • Never share a BYDUREON pen or needle with anyone else Sharing poses a risk for transmission of blood-borne pathogens

  • Acute Pancreatitis including fatal and non-fatal hemorrhagic or necrotizing pancreatitis has been reported. After initiation, observe patients carefully for symptoms of pancreatitis. If suspected, discontinue promptly and do not restart if confirmed. Consider other antidiabetic therapies in patients with a history of pancreatitis

  • 雷霆加速器ios永久免费Risk of hypoglycemia is increased when exenatide is coadministered with insulin or insulin secretagogues. Consider lowering the dose of these agents when coadministered with BYDUREON or BYDUREON BCise

  • 免费科学上外网 appMay induce nausea and vomiting with transient hypovolemia and may worsen renal function. Increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation have been reported. Not recommended in patients with eGFR <45 mL/min/1.73 m2

  • 菜鸟加速器Because exenatide is commonly associated with gastrointestinal adverse reactions, not recommended in patients with severe gastrointestinal disease (eg, gastroparesis)

  • Immunogenicity Patients may develop antibodies to exenatide. Patients with higher titer antibodies may have an attenuated HbA1c response. In clinical trials, attenuated glycemic response was associated with BYDUREON- or 菜鸟加速器官方下载 patients. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy

  • Hypersensitivity Reports of serious hypersensitivity reactions (eg, anaphylaxis and angioedema). If this occurs, patients should discontinue BYDUREON or BYDUREON BCise and promptly seek medical advice

  • 怎样关闭浏览器云加速-百度经验:2021-10-6 · 怎样关闭浏览器云加速,最近很多朋友咨询关于怎样关闭浏览器云加速的问题，今天的这篇经验就来聊一聊这个话题，希望可以 ... and associated bleeding has been reported with exenatide. Serious bleeding, which may be fatal, has been reported. Discontinue promptly if suspected and avoid re-exposure to exenatide

  • Injection-Site Reactions Serious reactions (eg, abscess, cellulitis, and necrosis), with or without subcutaneous nodules, have been reported

  • Acute Gallbladder Disease has been reported in 免费科学上外网 app receptor agonist trials, including exenatide. If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated

菜鸟加速器

  • Most common (≥5%) and occurring more frequently than comparator in BYDUREON clinical trials: nausea (16.9%), diarrhea (12.7%), headache (8.0%), vomiting (6.8%), constipation (5.9%), injection-site pruritus (5.9%), injection-site nodule (5.3%), dyspepsia (5.1%)

  • Most common (≥5%) in BYDUREON BCise clinical trials: injection-site nodule (10.5%), nausea (8.2%)

DRUG INTERACTIONS

  • Oral Medications BYDUREON and BYDUREON BCise slow gastric emptying and may reduce the rate of absorption of orally administered drugs

  • Warfarin Increased international normalized ratio (INR) sometimes associated with bleeding has been reported with concomitant use of exenatide with warfarin. Monitor INR frequently until stable upon initiation of BYDUREON or BYDUREON BCise

PREGNANCY

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

电脑国内google加速软件

BYDUREON and BYDUREON BCise are both indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

  • Not recommended as first-line therapy for patients inadequately controlled on diet and exercise

  • Not a substitute for insulin. Should not be used to treat type 1 diabetes or diabetic ketoacidosis

  • Not studied with prandial insulin

  • Do not coadminister with other exenatide-containing products

  • Not studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis

You may report side effects related to AstraZeneca products by clicking here.

Please see full Prescribing Information, including Boxed WARNINGS, for BYDUREON, and BYDUREON BCise.

WARNING: RISK OF THYROID C-CELL TUMORS

  • Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON or BYDUREON BCise cause thyroid 免费科学上外网 app tumors, including medullary thyroid carcinoma (MTC) in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined

  • BYDUREON and BYDUREON BCise are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with the use of BYDUREON or BYDUREON BCise and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with BYDUREON or BYDUREON BCise

CONTRAINDICATIONS

  • For BYDUREON and BYDUREON BCise: Personal or family history of MTC, patients with MEN 2

  • 菜鸟：今年天猫618快递提速超30% 网友：可怕的中国速度-菜 ...:2021-6-5 · &ldquo;这次天猫618，得益于数字化和智能化的加速普及，菜鸟和通达系快递速度，已经全面超越传统仓配物流速度。&rdquo;6月4日，天猫618菜鸟总指挥 ...

  • ARM处理器、X86处理器和AI处理器的区别 - 菜鸟-传奇 - 博客园:2021-11-2 · ARM处理器、X86处理器和AI处理器的区别 目前主要的处理器架构有： X86: Intel, AMD, 海光, 兆芯 ARM: 华为，飞腾，华芯通，Cavium，Ampere，富士通，亚马逊 POW

WARNINGS AND PRECAUTIONS

  • Acute Pancreatitis including fatal and non-fatal hemorrhagic or necrotizing pancreatitis has been reported. After initiation, observe patients carefully for symptoms of pancreatitis. If suspected, discontinue promptly and do not restart if confirmed. Consider other antidiabetic therapies in patients with a history of pancreatitis

  • Never Share Injection Device or Needle Between Patients Sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed

  • Hypoglycemia Risk of hypoglycemia is increased when exenatide is coadministered with insulin or insulin secretagogues. Consider lowering the dose of these agents when coadministered with BYDUREON, BYDUREON BCise or BYETTA

  • 雷霆加速器ios永久免费May induce nausea and vomiting with transient hypovolemia and may worsen renal function. Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation have been reported. BYDUREON or BYDUREON BCise are not recommended in patients with eGFR <45 mL/min/1.73 m2.  BYETTA should not be used in patients with severe renal impairment or end-stage renal disease and should be used with caution in patients with moderate renal impairment or renal transplantation

  • Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal adverse reactions, not recommended in patients with severe gastrointestinal disease (eg, gastroparesis)

  • Immunogenicity Patients may develop antibodies to exenatide. Patients with higher titer antibodies may have an attenuated HbA1c response. In clinical trials, attenuated glycemic response was associated with BYDUREON-, BYDUREON BCise-, or BYETTA-treated patients. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy

  • Hypersensitivity Reports of serious hypersensitivity reactions (eg, anaphylaxis and angioedema). If this occurs, patients should discontinue BYDUREON, BYDUREON BCise or BYETTA and promptly seek medical advice

  • Drug-induced, immune-mediated thrombocytopenia and associated bleeding have been reported with exenatide. Serious bleeding associated with profound thrombocytopenia may be potentially fatal. Discontinue promptly if suspected and avoid re-exposure to exenatide

  • Injection-Site Reactions Serious reactions (eg, abscess, cellulitis, and necrosis), with or without subcutaneous nodules, have been reported with extended-release exenatide

  • Acute Gallbladder Disease has been reported in GLP-1 receptor agonist trials, including exenatide. If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated

ADVERSE REACTIONS

  • Most common (≥5%) and occurring more frequently than comparator in BYDUREON clinical trials: nausea (16.9%), diarrhea (12.7%), headache (8.0%), vomiting (6.8%), constipation (5.9%), injection-site pruritus (5.9%), injection-site nodule (5.3%), dyspepsia (5.1%)

  • Most common (≥5%) in BYDUREON BCise clinical trials: injection-site nodule (10.5%), nausea (8.2%)

  • Most common (≥5%) and occurring more frequently than placebo in BYETTA clinical trials: nausea (8%-44%), hypoglycemia (3.8%-35.7%), vomiting (4%-18%), diarrhea (6%-18%), feeling jittery (9%), dizziness (9%), headache (9%-14%), dyspepsia (3%-7%), constipation (10%), asthenia (4%-5%)

DRUG INTERACTIONS

  • Oral Medications BYDUREON, BYDUREON BCise and BYETTA slow gastric emptying and may reduce the rate of absorption of orally administered drugs

  • Warfarin Increased international normalized ratio (INR) sometimes associated with bleeding has been reported with concomitant use of exenatide with warfarin. Monitor INR frequently until stable upon initiation of BYDUREON, BYDUREON BCise, or BYETTA

PREGNANCY

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

电脑国内google加速软件

BYDUREON, BYDUREON BCise and BYETTA are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

  • BYDUREON or BYDUREON BCise is not recommended as first-line therapy for patients inadequately controlled on diet and exercise

  • BYDUREON, BYDUREON BCise or BYETTA is not a substitute for insulin. Should not be used to treat type 1 diabetes or diabetic ketoacidosis

  • 菜鸟网络宣布 全国首个物联网机器人分拨中心在南京启用 ...:2021-6-12 · 登 录 注 册 钱 包 手机版

  • Do not coadminister with other exenatide-containing products

  • 2021 年 6月 14 日 随笔档案 - itprobie-菜鸟程序员 - 博客园:2021-6-14 · posted @ 2021-06-14 02:03 itprobie-菜鸟程序员 阅读(0) 评论(0) 推荐(0) 编辑 Docker 镜像加速 摘要：Docker 镜像加速 国内从 DockerHub 拉取镜像有时会遇到困难，此时可以配置镜像加速器。

迅游加速器 5.1.26.1免费版 2021.6.16更新 - 『精品软件区 ...:2021-6-17 · 迅游加速器版本 5.1.26.1免费版 2021.6.16更新相信大家都是老司机了，多的不说了链接在下方重点说一下，这款软件我会持续更新额！别的不要求 ... 迅游加速器 5.1.26.1免费版 2021.6.16更新 ,吾爱破解 - LCG - LSG |安卓破解|病毒分析|www.52pojie.cnhere.

Please see full Prescribing Information, including Boxed WARNINGS, for BYDUREON and BYDUREON BCise, and full Prescribing Information for BYETTA.

Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonist; T2D, type 2 diabetes.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. 使命召唤台服手游怎么开陀螺仪，菜鸟也能变枪神_biubiu加速器:使命召唤台服手游怎么开陀螺仪？使命召唤是一款力求达到真实现代战争场面的射击类手游，激烈的战斗和快节奏的操作经常让新手玩家应接不暇，其实大家都忽略了陀螺仪的使用，小编今天就给大家讲讲如何在使命召唤台服手游打开陀螺仪。在游戏主界面上点击设置选项，在其中的基本讯息里就能 ...

Abbreviations: FDA, US Food and Drug Administration; GLP-1 RA, glucagon-like peptide-1 receptor agonist.

References:

  1. BYETTA® ([exenatide] injection) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  3. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  4. Data on file, REF-14053, AstraZeneca Pharmaceuticals LP.

  5. Data on file, REF-33646, AstraZeneca Pharmaceuticals LP.

  6. Data on file, US-27454, IQVIA NPA data from 02/2012-01/2019, AstraZeneca Pharmaceuticals LP.

Abbreviations: AACE, American Association of Clinical Endocrinologists; GLP-1 RA, glucagon-like peptide-1 receptor agonist; T2D, type 2 diabetes.

References:

  1. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762-768.

  2. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(9):2041-2047.

  3. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.

  4. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  5. BYETTA® ([exenatide] injection) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  6. Van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. 菜鸟加速器官方下载. 2014;63(12):4186-4196.

  7. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997;160(4):413-422.

  8. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. 免费科学上外网 app. 2013;17(6):819-837.

  9. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(suppl 2):S127-S138.

  10. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. 菜鸟加速器. 2018;24(1):91-120.

  11. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183-190.

  12. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. doi:10.7573/dic.212283. Accessed April 19, 2018.

Abbreviations: BL, baseline; GLP-1 RA, glucagon-like peptide-1 receptor agonist; PK, pharmacokinetic; T2D, type 2 diabetes.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Data on file, REF-14053, AstraZeneca Pharmaceuticals LP.

Reference:

  1. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. 菜鸟加速器官方. 2011;13(11):1145-1154.

Abbreviations: FPG, fasting plasma glucose; PK, pharmacokinetic.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. 加速器下载_网游加速器安装板/免安装版下载-斧牛加速器:2021-6-1 · 斧牛加速 菜鸟变大神 斧牛加速前 登录困难，急死人 延迟高，白白送死 频繁卡顿、掉线被骂傻X 斧牛加速后 秒登录，心情爽 畅快击杀，战神再现 稳定游戏，爽快一夏

  3. Wysham CH, Rosenstock J, Vetter M, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165-172.

Abbreviations: BID, twice daily; BL, baseline; ITT, intent-to-treat; LSM, least-squares mean; QD, once daily; QW, once weekly; SU, sulfonylurea; T2D, type 2 diabetes; TZD, thiazolidinedione.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Data on file, REF-22126, AstraZeneca Pharmaceuticals LP.

  3. Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P; for the DURATION-NEO-2 study investigators. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19(7):979免费科学上外网 app.

  4. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):22菜鸟加速器43.

  5. Bergenstal RM, Wysham C, MacConell L, et al; for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.

  6. Russell-Jones D, Cuddihy RM, Hanefeld M, et al; on behalf of the DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. 雷霆加速器ios永久免费. 2012;35(2):252-258.

  7. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.

  8. Wysham CH, Rosenstock J, Vetter M, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165-172.

Abbreviations: AE, adverse event; BID, twice daily; GLP-1 RA, glucagon-like peptide-1 receptor agonist; ITT, intent-to-treat; QW, once weekly; SU, sulfonylurea; T2D, type 2 diabetes; TZD, thiazolidinedione.

References:

  1. Data on File, US-27454, IQVIA NPA data from 02/2012-01/2019, AstraZeneca Pharmaceuticals LP.

  2. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  3. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. 雷霆加速器ios永久免费. 2011;13(11):1145-1154.

  4. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  5. Data on file, RE-5087, AstraZeneca Pharmaceuticals LP.

  6. Wysham CH, Rosenstock J, Vetter M, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165-172.

Abbreviation: T2D, type 2 diabetes.

雷霆加速器ios永久免费

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Data on file, REF-14053, AstraZeneca Pharmaceuticals LP.

Abbreviations: CGM, continuous glucose monitoring; FPG, fasting plasma glucose; MET, metformin; mITT, modified intent-to-treat; MXR, metformin extended-release; PPG, postprandial glucose.

References:

  1. 狂野飙车7加速器跑法菜鸟视频_游戏狗狂野飙车7专区 ...:2021-1-13 · 狂野飙车7加速器跑法菜鸟视频，第一圈有点醉驾，扭来扭去，第二圈可以看到基本上都是在极速状态刚好结束的时候踩上了加速器。来看狂野飙车7加速器跑法菜鸟视频

  2. Frias JP, Nakhle S, Ruggles JA, et al. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial [published online ahead of print August 16, 2016]. Diabetes Obes Metab. doi:10.1111/dom.12763.

Abbreviations: BL, baseline; IG, insulin glargine; LS, least squares; MET, metformin; SU, sulfonylurea; TZD, thiazolidinediones.

References:

  1. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.

  3. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-1016.

Abbreviations: BID, twice daily; IU, international unit; QW, once weekly.

References:

  1. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Data on file, REF-7842. AstraZeneca Pharmaceuticals LP.

  3. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.

  4. Wysham CH, Philis-Tsimikas A, Klein EJ, et al. DURATION-1 extension in patients with type 2 diabetes: efficacy and tolerability of exenatide once weekly over 7 years [poster]. Presented at: 76th Annual Scientific Sessions of American Diabetes Association; June 10-14, 2016; New Orleans, LA. Poster 1041-P.

  5. Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464-473.

  6. Data on file, REF-5090. AstraZeneca Pharmaceuticals LP.

  7. Data on file, REF-4977. AstraZeneca Pharmaceuticals LP.

Abbreviations: PK, pharmacokinetics.

雷霆加速器ios永久免费

  1. BYDUREON® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

Reference:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

Reference:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

Abbreviations: BL, baseline; CV, cardiovascular; GLP-1 RA, glucagon-like peptide-1 receptor agonist; T2D, type 2 diabetes.

References:

  1. BYDUREON BCise® ([exenatide extended-release] injectable suspension) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. 雷霆加速器ios永久免费 2017;377(13):1228-1239.